Apr 10 |
ABVC Biopharma stock climbs on deal for its oncology/hematology products
|
Apr 10 |
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
|
Mar 26 |
Why ABVC BioPharma Stock Is Up Today
|
Mar 26 |
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
|
Mar 21 |
AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars
|
Mar 14 |
ABVC BioPharma GAAP EPS of -$2.43, revenue of $0.15M
|
Mar 14 |
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
|
Feb 27 |
ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars
|
Feb 15 |
ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues
|
Feb 8 |
ABVC BioPharma to acquire real estate worth $2.96M in Taiwan
|